News Breaks |
|
|
| September 27, 2012 |
| 05:44 EDT |  | RDY, MRK | Dr. Reddy’s announces the launch of Montelukast Sodium Oral Granules
Dr. Reddy’s Laboratories (RDY) announced that it has launched Montelukast Sodium Oral Granules, a bioequivalent generic version of Singulair, or montelukast sodium, oral granules in the U.S. market on Sept. 26, following the approval by the U.S. FDA of Dr.Reddy’s ANDA for Montelukast Sodium Oral Granules. The Singulair Oral Granules brand had U.S. sales of approximately $61 million for the most recent twelve months ending July 2012 according to IMS Health. Dr. Reddy’s Montelukast Sodium Oral Granules in 4 mg are available in unit dosage package of 30. Singulair is a registered trademark of Merck (MRK). |
|
|
News For RDY;MRK From The Last 14 Days Check below for free stories on RDY;MRK the last two weeks. |
|
|
| May 22, 2013 |
| 18:06 EDT |  | MRK | Merck insomnia drug gets FDA panel backing, WSJ reports
Merck's insomnia drug suvorexant received a favorable 13-3 vote from an FDA panel on the drug's two proposed starting doses, with the panel splitting the vote on the safety of higher doses, reports the Wall Street Journal. Reference Link |
|
| 16:16 EDT | | MRK | FDA panel votes 13-3 that Merck insomnia drug safe in low doses, Bloomberg says
 Subscribe for More Information |
|
| 16:00 EDT |  | MRK | Options Update; May 22, 2013
Subscribe for More Information |
|
| 14:52 EDT | | MRK | FDA panel says Merck insomnia drug effective as sleep aid, Bloomberg reports
Subscribe for More Information |
|
| 09:39 EDT | | MRK | Active equity option families trading
Subscribe for More Information |
|
| 07:45 EDT |  | MRK | FDA Peripheral & Central Nervous System Drugs Advisory Committee holds a meeting
Subscribe for More Information |
|
| May 21, 2013 |
| 18:56 EDT | | MRK | On The Fly: After Hours Movers
Subscribe for More Information |
|
| 17:03 EDT | | MRK | Merck announces $5B share repurchase
Subscribe for More Information |
|
| 17:01 EDT | | MRK | Merck announces $5B accelerated share repurchase
Subscribe for More Information |
|
| 07:44 EDT | | MRK | Sachs Associates to host a forum
Subscribe for More Information |
| |
| May 20, 2013 |
| 17:49 EDT | | MRK | Merck sleep drug effective, dosages questioned, WSJ reports
Subscribe for More Information |
|
| 07:32 EDT | | MRK | Society for Information Display / IHS to host a conference
Display Week 2013 is being held in Vancouver, British Columbia on May 19-24. |
|
| May 16, 2013 |
| 08:55 EDT | | MRK | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information |
|
| May 14, 2013 |
| 17:39 EDT | | MRK | Moody's lowers Merck's guaranteed debt to A1 from Aa3; stable outlook
Moody's Investors Service lowered the long-term ratings of Merck by one notch, including the guaranteed senior unsecured rating to A1 from Aa3 and the non-guaranteed senior unsecured rating to A2 from A1. This action concludes a review for downgrade initiated on May 1, 2013. At the same time, Moody's affirmed Merck's Prime-1 commercial paper rating. The rating outlook is stable. |
|
| 06:12 EDT |  | RDY | Dr. Reddy's Labs reports Q4 EPS 60c, one estimate 54c
Subscribe for More Information |
|
| May 10, 2013 |
| 11:48 EDT | | MRK | Drugmakers to face pressure on U.S. prices, Reuters says
Subscribe for More Information |
|
| 06:53 EDT | | MRK | GlaxoSmithKline, Merck to discount cancer vaccine in poor nations, NY Times says
Subscribe for More Information |
|
| May 9, 2013 |
| 07:22 EDT | | MRK | Merck awarded significant portion of UNICEF HPV vaccine tender
Subscribe for More Information |
|
| May 8, 2013 |
| 08:32 EDT | | MRK | Merck says FDA accepts biologics license application for allergy tablet
Merck announced that the Biologics License Application for its investigational ragweed pollen sublingual allergy immunotherapy tablet has been accepted for review by the U.S. Food and Drug Administration. The BLA for Merck’s investigational ragweed pollen sublingual allergy immunotherapy tablet is supported by five studies evaluating the efficacy and safety of the tablet in adults, 18 years of age or older, with ragweed induced allergic rhinitis. On March 27, Merck announced that the FDA had also accepted the BLA for its investigational Timothy grass pollen sublingual allergy immunotherapy tablet. Merck expects the FDA’s review for both to be completed in the first half of 2014. |
|
|
|
|
|
